AstraZeneca PLC (LSE:AZN) Annual Report 2022

The latest annual report of AstraZeneca PLC (AZN) was published on 31 Dec 2022. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - AZN Annual Results

Amounts in USD

Total Revenue
Gross Profit
Net Tangible Assets
Net Income
Capital Expenditures

AZN Income Statement 2022 Annual Report

As per the latest Income Statement of AZN, the Net revenue increased by $6.934B (19%) compared to the previous period. The operating income in 2022 increased by $3.62B (68%). The net income as per the annual report was 3.29B which increased by $3.176B (2836%) compared to previous year.

Income Statement Report (2022/2021)

2022 2021
Total Revenue 44.35B 37.42B
Gross Profit 35.73B 27.62B
Operating Income 8.96B 5.34B
Income Before Tax 2.5B -265M
Net Income 3.29B 112M

Balance Sheet - AZN 2022 Annual Report

Read further: AZN Balance Sheet Detailed Analysis

The latest balance sheet from annual result of AstraZeneca PLC showed the company reduced the cash on balance sheet by $-163.00M (-3%). The Net tangible assets of AZN on the balance sheet were at -22.09B which is $1.026B (4%) more than previous annual report. The total stockholder equity also decreased by $-2.231B (-6%) compared to previous reporting period.

Balance Sheet Statement Report (2022/2021)

2022 2021
Cash 6.17B 6.33B
Total Assets 96.48B 105.36B
Long Term Debt 23.91B 29.72B
Total Liabilities 59.42B 66.08B
Total Shareholder Equity 37.04B 39.27B
Net Tangible Assets -22.09B -23.12B

Cash Flow Statement - AZN 2022 Annual Report

The 2022 annual cash flow statement of AstraZeneca PLC showed that the net income increased by $3.176B (2836%) compared to previous reporting period. Also the capital expenditure of AZN increased by $0 (0%).

As of 2022, the total cash from investing activities was -2.96B and total cash from financing activities was -6.82B.

Cash Flow Statement Report (2022/2021)

2022 2021
Net Income 3.29B 112M
Capital Expenditures -1.09B -1.09B
Dividends Paid -4.36B -3.86B
Total Cash From From Investing Activities -2.96B -11.06B
Total Cash From From Financing Activities -6.82B 3.65B

AstraZeneca PLC Annual Report History

Income Statement

Income Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Total Revenue 44.35B 37.42B 26.62B 24.38B
Cost Of Revenue 8.62B 9.8B 5.25B 4.85B
Gross Profit 35.73B 27.62B 21.37B 19.54B
Research Development 9.53B 8.02B 5.9B 5.35B
Selling General Administrative 17.47B 14.46B 11.59B 11.44B
Non Recurring - - - -
Other Operating Expenses -231M -207M -486M -319M
Total Operating Expenses 35.39B 32.07B 22.25B 21.32B
Operating Income 8.96B 5.34B 4.37B 3.07B
Total Other Income Expense Net -6.46B -5.61B -454M -1.52B
Ebit 8.96B 5.34B 4.37B 3.07B
Interest Expense -917M -776M -738M -780M
Income Before Tax 2.5B -265M 3.92B 1.55B
Income Tax Expense -792M -380M 772M 321M
Minority Interest 21M 19M 16M 1.47B
Net Income From Continuing Ops 3.29B 115M 3.14B 1.23B
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income 3.29B 112M 3.2B 1.33B
Net Income Applicable To Common Shares 3.29B 112M 3.2B 1.33B

Balance Sheet Statement

Balance Sheet Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Cash 6.17B 6.33B 7.83B 5.37B
Short Term Investments 64M 53M 42M 38M
Net Receivables 9.92B 8.79B 5.65B 5.18B
Inventory 4.7B 8.98B 4.02B 3.19B
Other Current Assets 398M 556M 99M 106M
Total Current Assets 22.59B 26.24B 19.54B 15.56B
Long Term Investments 1.14B 1.26B 1.19B 1.51B
Property Plant Equipment 9.45B 10.17B 8.92B 8.34B
Good Will 19.82B 20B 11.85B 11.67B
Intangible Assets 39.31B 42.39B 20.95B 20.83B
Other Assets 4.17B 5.3B 4.28B 3.47B
Deferred Long Term Asset Charges 3.26B 4.33B 3.44B 2.72B
Total Assets 96.48B 105.36B 66.73B 61.38B
Accounts Payable 2.55B 2.82B 2.35B 1.77B
Short Long Term Debt 960M 2.25B 1.57B 1.63B
Other Current Liab 3.81B 4.52B 5.85B 4.9B
Long Term Debt 23.91B 29.72B 19.8B 17.89B
Other Liab 8.5B 13.01B 10.49B 10.28B
Minority Interest 21M 19M 16M 1.47B
Total Current Liabilities 26.29B 22.59B 20.31B 18.12B
Total Liab 59.42B 66.08B 51.09B 46.78B
Common Stock 387M 387M 328M 328M
Retained Earnings 3.12B 3.64B 6.44B 5B
Treasury Stock -1.62B 111M 881M -143M
Capital Surplus 35.16B 35.13B 7.97B 7.94B
Other Stockholder Equity -1.62B 111M 881M -143M
Total Stockholder Equity 37.04B 39.27B 15.62B 13.13B
Net Tangible Assets -22.09B -23.12B -17.17B -19.37B

Cash Flow Statement

Cash Flow Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net Income 3.29B 112M 3.2B 1.33B
Depreciation 5.18B 4.04B 2.83B 2.71B
Change To Netincome -2.49B -272M -1.65B -802M
Change To Account Receivables -1.35B -961M -739M -898M
Change To Liabilities 1.17B 1.41B 1.72B 868M
Change To Inventory 3.94B 1.58B -621M -316M
Total Cash From Operating Activities 9.81B 5.96B 4.8B 2.97B
Capital Expenditures -1.09B -1.09B -961M -979M
Investments -143M 605M 2B 125M
Other Cashflows From Investing Activities 60M 54M 87M 274M
Total Cashflows From Investing Activities -2.96B -11.06B -285M -657M
Dividends Paid -4.36B -3.86B -3.57B -3.59B
Net Borrowings -1.44B 7.65B 1.44B -1.7B
Other Cashflows From Financing Activities -1.05B -178M -101M 4M
Total Cash From Financing Activities -6.82B 3.65B -2.2B -1.76B
Effect Of Exchange Rate -80M -62M 12M 5M
Change In Cash -55M -1.51B 2.32B 552M
Issuance Of Stock 29M 29M 30M 3.52B